摘要
目的探讨罗格列酮对体外培养肝星状细胞MMP-2及TIMP-1基因表达的影响。方法采用HSC-T6肝星状细胞系,经不同浓度的罗格列酮干预,采用RT-PCRA法检测各组MMP-2及TIMP-1基因的表达情况。结果在10、20μmol/L罗格列酮组,TIMP-1的表达较空白对照组明显降低(P<0.05),而MMP-2的表达与空白对照组相比差异无统计学意义。结论罗格列酮的抗肝纤维化作用与抑制HSC表达TIMP-1有关。
Objective To investigate the effects of Rosiglitazone on expressions of MMP-2 and TIMP-1 mRNA in hepatic stellate cells（HSCs） in vitro.Methods The HSC line,HSC-T6 was incubated with different concentrations of Rosiglitazone.The MMP-2 and TIMP-1 mRNA levels were measured by reverse-transcription polymerase chain reaction（RT-PCR）.Results Expression of TIMP-1 mRNA in the Rosiglitazone-treatment groups was significantly lower than that in the control group（P〈0.05）,and there was no difference in the MMP-2 mRNA levels between the Rosiglitazone-treatment groups and the control group.Conclusion The anti-fibrosis mechanism of Rosiglitazone is partly due to its down-regulation on TIMP-1 but not on MMP-2 expression of hepatic stellate cells.
出处
《山东大学学报（医学版）》
CAS
北大核心
2009年第11期74-75,79,共3页
Journal of Shandong University:Health Sciences
